Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.55 HKD | +0.99% |
|
+3.02% | -6.41% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.41% | 1.01B | - | ||
+15.20% | 121B | B+ | ||
+19.67% | 113B | B+ | ||
+18.95% | 26.02B | B | ||
-23.86% | 19.39B | B+ | ||
-19.03% | 15.91B | A- | ||
-20.90% | 15.09B | B | ||
-46.14% | 15.06B | A- | ||
+63.85% | 14.93B | C+ | ||
+4.49% | 13.85B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6855 Stock
- Ratings Ascentage Pharma Group International